Citius Pharmaceuticals, Inc. (CTXR) Financial Statements (2026 and earlier)

Company Profile

Business Address 11 COMMERCE DRIVE
CRANFORD, NJ 07016
State of Incorp. NV
Fiscal Year End September 30
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

3/31/2026
Q2
12/31/2025
Q1
9/30/2025
Q4
6/30/2025
Q3
3/31/2025
Q2
12/31/2024
Q1
9/30/2024
Q4
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments7,7214,2526,089261,1003,252
Cash and cash equivalent7,7214,2526,089261,1003,252
Receivables4,049     
Inventory, net of allowances, customer advances and progress billings22,63922,28717,20915,33914,3818,269
Inventory22,63922,28717,20915,33914,3818,269
Prepaid expense3,5351,3951,3133,0092,8462,700
Total current assets:37,94527,93424,61118,37418,32714,221
Noncurrent Assets
Operating lease, right-of-use asset835819881922191246
Other noncurrent assets101,611102,185102,185102,185102,185102,185
Total noncurrent assets:102,447103,004103,066103,107102,376102,431
TOTAL ASSETS:140,392130,938127,677121,481120,703116,652
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities15,71517,88418,61818,14713,6064,944
Accounts payable11,02113,69410,0949,3687,3644,927
Accrued liabilities4,6934,1908,5248,7796,24217
Debt 1,0001,0001,000   
Other undisclosed current liabilities21,49226,03132,22531,72931,20030,871
Total current liabilities:38,20744,91551,84249,87744,80635,815
Noncurrent Liabilities
Liabilities, other than long-term debt8,7178,4968,2738,0296,9786,735
Deferred income tax liabilities8,0357,7717,5077,2426,9786,714
Operating lease, liability682725767787 21
Total noncurrent liabilities:8,7178,4968,2738,0296,9786,735
Total liabilities:46,92453,41060,11657,90651,78442,550
Equity
Equity, attributable to parent79,95867,55065,05960,65965,40870,077
Common stock221814987
Additional paid in capital326,961306,336295,889282,706276,539271,440
Accumulated deficit(247,025)(238,804)(230,845)(222,055)(211,138)(201,370)
Equity, attributable to noncontrolling interest13,5109,9772,5022,9163,5114,024
Total equity:93,46877,52867,56163,57668,91974,102
TOTAL LIABILITIES AND EQUITY:140,392130,938127,677121,481120,703116,652

Income Statement (P&L) ($ in thousands)

3/31/2026
Q2
12/31/2025
Q1
9/30/2025
Q4
6/30/2025
Q3
3/31/2025
Q2
12/31/2024
Q1
9/30/2024
Q4
Revenues3,944     
Cost of revenue(789)     
Gross profit:3,155     
Operating expenses(12,174)(8,437)(8,788)(11,261)(10,040)(11,050)
Operating loss:(9,019)(8,437)(8,788)(11,261)(10,040)(11,050)
Nonoperating income (expense)(110)(42)(152)1323117
Investment income, nonoperating4553211323117
Interest and debt expense(46)(107)(172)   
Loss from continuing operations before equity method investments, income taxes:(9,175)(8,586)(9,112)(11,247)(10,017)(10,933)
Other undisclosed income from continuing operations before income taxes46107172   
Loss from continuing operations before income taxes:(9,130)(8,479)(8,940)(11,247)(10,017)(10,933)
Income tax expense (benefit)(264)(264)(264)(264)(264)(144)
Net loss:(9,394)(8,744)(9,204)(11,512)(10,281)(11,077)
Net income attributable to noncontrolling interest1,173784414595513 
Other undisclosed net income (loss) attributable to parent    (595) 287
Net loss attributable to parent:(8,221)(7,959)(8,790)(11,512)(9,768)(10,790)
Other undisclosed net income (loss) available to common stockholders, basic    595 (726)
Net loss available to common stockholders, diluted:(8,221)(7,959)(8,790)(10,917)(9,768)(11,516)

Comprehensive Income ($ in thousands)

3/31/2026
Q2
12/31/2025
Q1
9/30/2025
Q4
6/30/2025
Q3
3/31/2025
Q2
12/31/2024
Q1
9/30/2024
Q4
Net loss:(9,394)(8,744)(9,204)(11,512)(10,281)(11,077)
Comprehensive loss:(9,394)(8,744)(9,204)(11,512)(10,281)(11,077)
Comprehensive income, net of tax, attributable to noncontrolling interest1,173784414595513 
Other undisclosed comprehensive income, net of tax, attributable to parent      287
Comprehensive loss, net of tax, attributable to parent:(8,221)(7,959)(8,790)(10,917)(9,768)(10,790)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: